Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Sep 16:14:1337-1350.
doi: 10.2147/IJWH.S372597. eCollection 2022.

Mirabegron in the Management of Overactive Bladder Syndrome

Miriam O'Kane  1 , Dudley Robinson  1 , Linda Cardozo  1 , Adrian Wagg  2 , Paul Abrams  3
Affiliations
Review

Mirabegron in the Management of Overactive Bladder Syndrome

Miriam O'Kane et al. Int J Womens Health. .

Abstract

Overactive bladder (OAB) negatively affects work productivity and quality of life in sufferers. Its overall impact is likely to increase as a result of increasing prevalence in an ageing population. The pathophysiology of OAB is not completely understood but the β3-adrenoceptor, which is highly expressed in the urinary bladder, is thought to be important for mediating human detrusor relaxation during the storage phase. Clinical trial results have demonstrated that mirabegron, a selective β3-adrenoceptor agonist offers substantial clinical efficacy and good adherence rates over 12 months. Furthermore, due to its different mechanism of action, it is likely to offer a favourable tolerability profile when compared with antimuscarinic agents, resulting in improved persistence over long-term treatment. Finally, from a health economic perspective, despite its higher drug acquisition cost, mirabegron has been found to be cost-effective, owing to the greater increase in quality-adjusted-life-years gained, when compared to antimuscarinic medications. The PubMed database was searched for English language articles published between 1 January 2005 to 31 January 2022, on the subject of mirabegron. Search terms included "mirabegron", "overactive bladder", "β3-adrenoceptor agonist", "urinary incontinence". This review summarises the evidence for mirabegron as a treatment option for the management of OAB.

Keywords: drug therapy; mirabegron; overactive bladder; urinary incontinence; β3-adrenoceptor agonist.

PubMed Disclaimer

Conflict of interest statement

DR has received financial support from Astellas, Pfizer, Allergan, Ferring, and Ixaltis. LC has received funding for research, consultancy and speaker fees from Allergan, Astellas, BMR, Pfizer and Syner-Med. AW has received financial support from Astellas Pharma, SCA, Duchesnay (Canada), Urovant sciences, and Easily hygiene & health; Pfizer Corp for research, consultancy, and speaker fees. PA has received financial support from Astellas, Ferring, Ipsen, Sun Pharma, Cipla, Chiltern, Sanofi, Procter and Gamble, and Pfizer for research, consultancy, and speaker fees. The authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26. doi:10.1007/s00192-009-0976-9 - DOI - PubMed
    1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21(2):167–178. doi:10.1002/nau.10052 - DOI - PubMed
    1. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int. 2011;108(7):1132–1138. doi:10.1111/j.1464-410X.2010.09993.x - DOI - PubMed
    1. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7(4):455–463. doi:10.1111/j.1524-4733.2004.74008.x - DOI - PubMed
    1. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–1395. doi:10.1111/j.1464-410X.2008.07601.x - DOI - PubMed

LinkOut - more resources